Treatment of Attention-Deficit/Hyperactivity Disorder with Medication in Children with Autism Spectrum Disorder With and Without Intellectual Disability: A DBPNet Study

J Autism Dev Disord. 2023 Aug;53(8):3144-3150. doi: 10.1007/s10803-022-05611-1. Epub 2022 May 28.

Abstract

Children with autism spectrum disorder (ASD) and intellectual disability (ID)/global delay (GD) frequently have symptoms of attention-deficit/hyperactivity disorder (ADHD). We describe the practice patterns of developmental behavioral pediatricians (DBPs) in the treatment of children with ASD and coexisting ADHD and compare medication classes for children with and without intellectual disability. In bivariate analyses, we compared demographic characteristics, co-occurring conditions, and medication classes for children with and without intellectual disability. Significantly more patients with ID/GD were prescribed α-agonists than patients without ID/GD, but the difference was no longer significant when controlling for age in logistic regression children with ID/GD had more comorbidities and were more likely to be prescribed more than on psychotropic medication. In conclusion, age rather than ID/GD was associated with medication choice.

Keywords: ADHD; Autism; Intellectual disability; Medication.

MeSH terms

  • Attention Deficit Disorder with Hyperactivity* / complications
  • Attention Deficit Disorder with Hyperactivity* / drug therapy
  • Attention Deficit Disorder with Hyperactivity* / epidemiology
  • Autism Spectrum Disorder* / complications
  • Autism Spectrum Disorder* / drug therapy
  • Autism Spectrum Disorder* / epidemiology
  • Child
  • Comorbidity
  • Humans
  • Intellectual Disability* / complications
  • Intellectual Disability* / drug therapy
  • Intellectual Disability* / epidemiology
  • Psychotropic Drugs / therapeutic use

Substances

  • Psychotropic Drugs